JNJ · News · 20261030N

Product / Drug Pipeline Progress

JOHNSON & JOHNSON · 2026-10-30 · Importance 34 · Surprise 42

Johnson & Johnson’s investigational oral therapy JNJ-6143 showed a 75% overall response rate in a phase 1 study of heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC). The first-in-class RIPTAC molecule targets androgen receptor and BRD4 to induce cancer-cell death. The reported safety and efficacy findings led to initiation of a phase 2 study using the recommended 50 mg once-daily dose.

Key facts

• Johnson & Johnson initiated a phase 2 study of JNJ-6143 at the recommended 50 mg once-daily dose. source
• Johnson & Johnson's investigational oral therapy JNJ-6143 demonstrated a 75% overall response rate and significant PSA declines in heavily pretreated patients with metastatic castration-resistant prostate cancer in a phase 1 study. source